AnaptysBio Inc (NASDAQ:ANAB)’s share price traded up 9.9% on Monday . The company traded as high as $110.00 and last traded at $101.95. 2,305,700 shares were traded during mid-day trading, an increase of 537% from the average session volume of 362,019 shares. The stock had previously closed at $92.80.

A number of equities analysts have weighed in on the stock. Royal Bank of Canada reaffirmed a “hold” rating and issued a $84.00 target price on shares of AnaptysBio in a research note on Wednesday, August 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $121.00 target price on shares of AnaptysBio in a research note on Tuesday, August 7th. Zacks Investment Research raised shares of AnaptysBio from a “hold” rating to a “buy” rating and set a $93.00 target price for the company in a research note on Monday, August 13th. Wedbush reaffirmed an “outperform” rating and issued a $138.00 target price on shares of AnaptysBio in a research note on Tuesday, September 18th. Finally, Credit Suisse Group started coverage on shares of AnaptysBio in a research report on Thursday, July 19th. They set an “outperform” rating and a $104.00 price target for the company. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $125.00.

The company has a debt-to-equity ratio of 0.01, a quick ratio of 16.19 and a current ratio of 16.19.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.70) by $0.13. analysts anticipate that AnaptysBio Inc will post -2.69 earnings per share for the current year.

Large investors have recently modified their holdings of the company. Quantitative Systematic Strategies LLC acquired a new stake in shares of AnaptysBio during the 2nd quarter worth approximately $211,000. Asymmetry Capital Management L.P. acquired a new stake in shares of AnaptysBio during the 2nd quarter worth approximately $2,893,000. Janus Henderson Group PLC grew its position in shares of AnaptysBio by 45.3% during the 2nd quarter. Janus Henderson Group PLC now owns 2,830,322 shares of the biotechnology company’s stock worth $201,066,000 after buying an additional 882,440 shares during the period. Brown Advisory Inc. grew its position in shares of AnaptysBio by 1.5% during the 2nd quarter. Brown Advisory Inc. now owns 102,114 shares of the biotechnology company’s stock worth $7,253,000 after buying an additional 1,500 shares during the period. Finally, Handelsbanken Fonder AB grew its position in shares of AnaptysBio by 100.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 16,000 shares of the biotechnology company’s stock worth $1,137,000 after buying an additional 8,000 shares during the period.

About AnaptysBio (NASDAQ:ANAB)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

Read More: Market Capitalization

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.